Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.375 GBX | -2.17% | -.--% | -3.57% |
04-17 | ReNeuron Group Reports CFO Resignation | MT |
04-17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell-based Therapies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +31.51% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, United States, China and South East Asia
74.3
%
| 0 | 70.5 % | 0 | 74.3 % | +38.73% |
United States
25.7
%
| 0 | 29.5 % | 0 | 25.7 % | +14.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Hawkins
DFI | Director of Finance/CFO | 58 | 14-09-30 |
Suzanne Hancock
COO | Chief Operating Officer | - | 16-12-31 |
Chief Tech/Sci/R&D Officer | - | 22-03-02 | |
Simon Dew
PRN | Corporate Officer/Principal | - | 22-10-31 |
Shaun Stapleton
LAW | General Counsel | - | 15-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 22-03-21 |
Iain Ross
CHM | Chairman | 71 | 21-06-30 |
Director/Board Member | 61 | 21-07-13 | |
Michael Owen
BRD | Director/Board Member | 73 | 15-12-03 |
John Hawkins
DFI | Director of Finance/CFO | 58 | 14-09-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 57,173,760 | 44,745,727 ( 78.26 %) | 0 | 78.26 % |
Company contact information
Sector
Sales per region
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.57% | 2.41M | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |
- Stock Market
- Equities
- RENE Stock
- Company ReNeuron Group plc